查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1585818

液态切片测试设备市场：按报价、循环生物标记、最终用户、应用 - 2025-2030 年全球预测

Breast Cancer Liquid Biopsy Testing Devices Market by Offerings (Assay & Reagents Kits, Instruments), Circulating Biomarker (Circulating Tumar DNA, Circulating Tumor Cell, Extracellular Vesicles), End-User, Appplication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

乳癌液态切片检测设备市场2023年价值8.5876亿美元，预计2024年将达到10.236亿美元，复合年增长率为19.59%，到2030年将达30.0457亿美元。

乳癌液态切片检测设备的范围和定义包括旨在检测血液中循环的肿瘤细胞和DNA的诊断工具，为传统切片检查提供非侵入性替代方案。这些设备对于癌症的早期检测、监测疾病进展和个人化治疗计划至关重要，这使得它们对于精准医疗至关重要。应用范围包括临床诊断、治疗监测和预后预测，最终用途为医院、诊断实验室和研究机构。推动乳癌液态切片市场的主要成长要素包括癌症发生率的增加、对非侵入性手术的需求增加以及分子​​生物学技术的进步。最近的潜在商机在于人工智慧和机器学习的集成，以提高资料分析的准确性，以及扩大早期检测和即时监控的应用，特别是在医疗基础设施正在发展的发展中地区。然而，该市场面临一些限制，例如先进测试的高成本、监管障碍以及医生和患者意识有限。解决测试敏感性和特异性方面的挑战对于更广泛的采用仍然至关重要。创新的最佳领域包括改善生物标记发现、降低营运成本以及利用次世代定序和其他基因组技术增强测试预测能力。对乳癌异质性及其复杂生物学的研究可能会进一步优化这些检测仪器的有效性。市场本质上是动态的，技术发展迅速，传统切片检查方法面临竞争压力。为了保持竞争力，公司应专注于合作研究伙伴关係关係，利用巨量资料进行个人化医疗，并增加研发投资。利用新的商机需要加强教育、监管推广和策略联盟，以帮助驾驭复杂的医疗保健系统，并有效地将具有成本效益的解决方案推向市场。

主要市场统计
基准年[2023] 85876万美元
预测年份 [2024] 10.236 亿美元
预测年份 [2030] 3,004,570,000 美元
复合年增长率（%） 19.59%

市场动态：快速发展的乳癌液态切片测试设备市场的关键市场洞察

液态切片检测设备市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 世界各地女性乳癌发生率不断上升
    • 对非侵入性乳癌治疗的需求不断增长
    • 乳癌预筛检计画的激增
  • 市场限制因素
    • 对检测设备准确性的担忧
  • 市场机会
    • 液态切片检测设备的技术进展
    • 乳癌检测的研发投资
  • 市场挑战
    • 液态切片有严格的标准

波特五力：开拓液态切片测试设备市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解液态切片检测设备市场的外部影响

外部宏观环境因素在塑造液态切片测试设备市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解液态切片检测设备市场竞争格局

对液态切片测试设备市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵乳癌液态切片测试设备市场供应商的绩效评估

FPNV 定位矩阵是评估液态切片测试设备市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘乳癌液态切片测试设备市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对液态切片测试设备市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球女性乳癌发生率正在上升
      • 对非侵入性乳癌治疗的需求增加
      • 乳癌预筛检计画的激增
    • 抑制因素
      • 对检测设备准确性的担忧
    • 机会
      • 液态切片检测设备的技术进展
      • 乳癌检测研发投资
    • 任务
      • 液态生物检体有严格的标准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章液态切片检测设备市场：透过提供

  • 测定和试剂组
  • 装置

第七章液态切片检测设备市场：透过循环生物标记

  • 循环肿瘤DNA
  • 循环性肿瘤细胞
  • 细胞外囊泡

第八章液态切片测试设备市场：依最终用户分类

  • 医院
  • 研究室

第九章液态切片检测设备市场：依应用分类

  • 诊断
  • 监视
  • 筛检/早期发现
  • 治疗选择

第十章 北美和南美液态切片检测设备市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区液态切片检测设备市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲液态切片检测设备市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • BioVIew Ltd.
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Isogen Life Science BV
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Menarini Group
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Neogenomics Laboratories, Inc.
  • OncoDNA SA
  • Qiagen NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 858.76 million in 2023, expected to reach USD 1,023.60 million in 2024, and is projected to grow at a CAGR of 19.59%, to USD 3,004.57 million by 2030.

The scope and definition of breast cancer liquid biopsy testing devices encompass diagnostic tools designed to detect cancer cells or DNA from tumors circulating in the blood, offering a non-invasive alternative to traditional biopsies. These devices are crucial for early cancer detection, monitoring disease progression, and personalizing treatment plans, making them indispensable in precision medicine. The application scope spans clinical diagnostics, treatment monitoring, and prognosis, with end-use sectors including hospitals, diagnostic laboratories, and research institutions. Key growth factors driving the breast cancer liquid biopsy market include increasing cancer prevalence, rising demand for non-invasive procedures, and advancements in molecular biology technology. Recent potential opportunities lie in the integration of artificial intelligence and machine learning to enhance data analysis accuracy, as well as expanding applications in early-stage detection and real-time monitoring, particularly in developing regions with growing healthcare infrastructure. However, the market faces limitations such as high costs of advanced testing, regulatory hurdles, and limited awareness among practitioners and patients. Addressing challenges around sensitivity and specificity of tests remains crucial for broader adoption. Best areas for innovation include improving biomarker discovery, reducing operational costs, and enhancing the test's predictive capabilities through next-generation sequencing and other genomic technologies. Research into the heterogeneity of breast cancer and its complex biology may further optimize the efficacy of these devices. The market is inherently dynamic, with rapid technological evolution and competitive pressures from traditional biopsy methods. Companies should focus on collaborative research partnerships, leveraging big data for personalized medicine, and increased investment in R&D to maintain a competitive edge. To capitalize on emerging opportunities, there is a need for increasing educational efforts, regulatory advocacy, and strategic alliances that can help navigate complex healthcare systems and bring cost-effective solutions to market efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 858.76 million
Estimated Year [2024] USD 1,023.60 million
Forecast Year [2030] USD 3,004.57 million
CAGR (%) 19.59%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Testing Devices Market

The Breast Cancer Liquid Biopsy Testing Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer among women worldwide
    • Increasing demand for non-invasive breast cancer treatment
    • Surge in pre-screening programs for breast cancer detection
  • Market Restraints
    • Concerns related to the accuracy of testing devices
  • Market Opportunities
    • Technological advancements in breast cancer liquid biopsy testing devices
    • Investments in R&D for breast cancer testing
  • Market Challenges
    • Presence of strict standards for liquid biopsy

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Testing Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Testing Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Testing Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Testing Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Testing Devices Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Testing Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Testing Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Testing Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Testing Devices Market

A strategic analysis of the Breast Cancer Liquid Biopsy Testing Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., BioVIew Ltd., Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Isogen Life Science B.V., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., Menarini Group, Merck KGaA, Myriad Genetics, Inc., Natera Inc., Neogenomics Laboratories, Inc., OncoDNA SA, Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Testing Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offerings, market is studied across Assay & Reagents Kits and Instruments.
  • Based on Circulating Biomarker, market is studied across Circulating Tumar DNA, Circulating Tumor Cell, and Extracellular Vesicles.
  • Based on End-User, market is studied across Hospitals and Research Laboratories.
  • Based on Appplication, market is studied across Diagnosis, Monitoring, Screening/Early Detection, and Treatment Selection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer among women worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Surge in pre-screening programs for breast cancer detection
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns related to the accuracy of testing devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in breast cancer liquid biopsy testing devices
      • 5.1.3.2. Investments in R&D for breast cancer testing
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of strict standards for liquid biopsy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Testing Devices Market, by Offerings

  • 6.1. Introduction
  • 6.2. Assay & Reagents Kits
  • 6.3. Instruments

7. Breast Cancer Liquid Biopsy Testing Devices Market, by Circulating Biomarker

  • 7.1. Introduction
  • 7.2. Circulating Tumar DNA
  • 7.3. Circulating Tumor Cell
  • 7.4. Extracellular Vesicles

8. Breast Cancer Liquid Biopsy Testing Devices Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Laboratories

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Appplication

  • 9.1. Introduction
  • 9.2. Diagnosis
  • 9.3. Monitoring
  • 9.4. Screening/Early Detection
  • 9.5. Treatment Selection

10. Americas Breast Cancer Liquid Biopsy Testing Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Testing Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biocept, Inc.
  • 5. Biodesix, Inc.
  • 6. BioVIew Ltd.
  • 7. Eurofins Scientific SE
  • 8. Exact Sciences Corporation
  • 9. F. Hoffmann-La Roche AG
  • 10. Fluxion Biosciences Inc.
  • 11. Guardant Health, Inc.
  • 12. Illumina, Inc.
  • 13. Isogen Life Science B.V.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Laboratory Corporation of America Holdings
  • 16. Lucence Health Inc.
  • 17. Menarini Group
  • 18. Merck KGaA
  • 19. Myriad Genetics, Inc.
  • 20. Natera Inc.
  • 21. Neogenomics Laboratories, Inc.
  • 22. OncoDNA SA
  • 23. Qiagen N.V.
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ASSAY & REAGENTS KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMAR DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SCREENING/EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023